Year: 2023
Type: article
Study design: Clinical Trial
Abstract: Relevance: Genital endometriosis is the most common disease of the female reproductive system. Currently, 190 million women and adolescent girls worldwide suffer from this disease. Although many aspects of genital endometriosis have been scientifically studied, there is still a clinical need to improve the methods of diagnosis and treatment of symptoms associated with this disease. These issues are particularly relevant to the management of patients with adenomyosis. The aim of the study was to evaluate the clinical efficacy of indinol-3-carbinol and epigallocatechin-3-gallate in patients with adenomyosis. Methods: The study enrolled 72 patients with adenomyosis (mean age 34.1±3.2 years) who received indinol-3-carbinol and epigallocatechin-3-gallate for 6 months. The treatment efficacy was evaluated on the basis of the change in clinical symptoms of the disease and the dynamics of ultrasound criteria of adenomyosis. Results: After a 6-month course of therapy, there was a significant regression of disease symptoms and positive dynamics of changes in sonographic criteria of adenomyosis. No patient dropped out of the study and no patient experienced any significant side effects. Conclusion: Therapy with indinol-3-carbinol and epigallocatechin-3 is a promising method of adenomyosis treatment, taking into account a significant improvement in patients’ quality of life and the possibility to implement reproductive plans.
Authors: A.M. Doshchanova, A.S. Tuletova, L.K. Smailova
Institution: Astana Medical University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7218131587
